icon-folder.gif   Conference Reports for NATAP  
  64rd Annual Meeting of the
American Association for the
Study of Liver Diseases
Washington, DC Nov 1-5 2013
Back grey_arrow_rt.gif
Pharmacokinetics of Ledipasvir, an HCV-Specific NS5A Inhibitor, in HCV-Uninfected Subjects With Moderate or Severe Hepatic Impairment
  Reported by Jules Levin
AASLD 2013 Nov 1-4 Wash DC
Polina German,1 Anita Mathias,1 Jenny C. Yang,1 Lindsay McNair,1 Gong Shen,1 Mona Vimal,1 Edward J. Gane,2 William B. Smith,3 Gernot K. Klein,4 Thomas C. Marbury,5 Eric Lawitz6
1Gilead Sciences, Inc., Foster City, CA; 2New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand; 3New Orleans Center for Clinical Research, Knoxville, TN; 4APEX Research, Munich, Germany; 5Orlando Clinical Research Center, Orlando, FL; 6Texas Liver Institute, San Antonio, TX